Understand the source comparison
Tesamorelin vs Tesofensine: Which Peptide Better Targets Belly Fat and Weight Loss?
Tesamorelin and Tesofensine are both studied as fat reducing peptides, but they work in very different ways. Tesamorelin acts on growth hormone pathways, making it effective at lowering visceral belly fat. Research shows it reduces deep abdominal fat while lea
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tesamorelin and Tesofensine are both studied as fat reducing peptides, but they work in very different ways. Tesamorelin acts on growth hormone pathways, making it effective at lowering visceral belly fat. Research shows it reduces deep abdominal fat while leaving subcutaneous fat largely unchanged, which highlights its crucial role as a fat reducing peptide focused on visceral fat.
- Tesofensine works through neurotransmitter reuptake inhibition. By suppressing appetite and modestly raising energy use, it produces greater overall weight loss in trials. It also helps preserve lean muscle mass, giving it a body-composition benefit. Based on separate studies, Tesamorelin appears more effective for reducing visceral belly fat, whereas Tesofensine shows significant weight loss effects. No head-to-head trials have directly compared the two. The following table summarizes their differences:
- Main Target
- Visceral belly fat
- Overall body weight
- Key Mechanism
- Growth hormone → IGF-1 release
- Neurotransmitter reuptake inhibition
- Research Focus
- Abdominal fat, metabolic markers
- Appetite suppression, energy balance
- Body Composition Effect
- Reduces VAT, stable SAT
- Relatively preserves lean mass, lowers fat mass
- These insights set the stage for where fat reducing peptide research may be heading in the future.